Venus Remedies gets market nod for Bleomycin 15000 IU in UK
Mumbai: Venus Remedies has announced receipt of market authorization in the United Kingdom for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion by its German subsidiary, Venus Pharma GmbH.
Bleomycin 15,000 IU is a potent medication that contains the active ingredient bleomycin sulfate. It belongs to a group of medicines known as cytostatic drugs, specifically designed to combat cancer. This class of medications, often referred to as chemotherapy, is renowned for its effectiveness in targeting cancer cells and preventing their uncontrolled division.
Its versatile applications include the treatment of certain types of squamous cell carcinomas in the head and neck, cervix, and external genitalia. It also serves as a panacea in treating severe types of lymph node cancers, such as Hodgkin's disease and non-Hodgkin's lymphoma of intermediate and high malignancy, testicular cancer, and fluid accumulation in the lungs, often associated with cancer.
Bleomycin can be administered as a standalone treatment or in combination with other cancer medications and radiotherapy. Its effectiveness and utility in cancer treatment have earned it market authorizations in numerous countries worldwide.
Venus Remedies holds a total of 15 Market Authorizations (MA) for Bleomycin products across the globe. To make Bleomycin more accessible, the company has submitted sixteen additional applications to Ministries of Health (MOHs) around the world. Venus has secured 15 registrations for this drug across various regions, including Africa, Asia, the Middle East, the Commonwealth of Independent States (CIS), North America, and South America.
"At Venus, our mission is to improve the lives of cancer patients by providing cutting-edge treatments. The UK's market authorization for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion is a significant step towards realizing this mission. We remain dedicated to enhancing healthcare solutions and are committed to pursuing additional authorizations to reach even more patients in need," stated Saransh Chaudhary, CEO, Venus Medicine Research Center (VMRC).
Ashutosh Jain, CEO, Venus Pharma GmbH, expressed that obtaining market authorization from MHRA is a momentous accomplishment for Venus Pharma GmbH. It enables the company to play a pivotal role in advancing cancer care and improving the quality of life for patients facing this challenging disease.
Read also: Venus Remedies gets Saudi marketing approval for Enoxaparin in pre-filled syringes
